Fact CheckerSign in

NCT05748158Recruiting

A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program

Physiology of the Weight Reduced State

Source: ClinicalTrials.gov · Last updated 12 Jun 2026

Brief summary (registry, in English)

The goal of this clinical trial is to determine the physiological basis for the differences in weight regain among adults (25-59 years old) with obesity following participation in a behavioral weight loss program. Eligible participants will undergo a baseline evaluation after which they will enter an up to 20 week behavioral weight loss program with the goal of losing at least 7 percent of their baseline weight within 35 weeks. Participants who meet the weight loss goal will be asked to remain weight stable for 2 weeks after which they will undergo a clinical examination. They will then be observed for 1 year during which they will undergo 2 additional clinical examinations, one 4 months after completing the weight loss program, and the other 12 months after completing the weight loss program.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
205 (estimated)
First submitted
17 Feb 2023
Start date
29 Sept 2023
Primary completion date
Mar 2027
Lead sponsor
University of Pittsburgh
Diseases
Obesity
NCT number
NCT05748158

What you commit to

  • Study type: Interventional
  • Planned participants: 205
  • From 29 Sept 2023 to the primary completion date, Mar 2027
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Known or suspected abuse or misuse of alcohol, prescription drugs, or recreational drugs
  • Regularly taking medication or supplement known to affect appetite, energy expenditure, or weight (e.g. appetite suppressants, steroids-including inhaled steroids but not topical, alpha-blockers, beta-blockers, certain psychotropic medications)
  • Currently taking anticoagulant medication
  • Prior or planned bariatric surgery, endoscopic therapy, device-based therapy for obesity, liposuction, cryolipolysis, or abdominoplasty
  • Metal implants, piercings that cannot be removed, or metal-based tattoos or hair treatments
  • Inability to achieve weight stability (defined in section 4.2.1) during the 2 weeks prior to initiation of the baseline Doubly Labeled Water (DLW) assessment

Other illness

  • History of pulmonary embolus in the past 6 months
  • Cardiovascular disease (e.g. myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack) within the past 6 months
  • Current major depressive disorder or history of major depressive disorder within 2 years
  • Presently classified as being in New York Heart Association Class II or greater or dysrhythmia
  • Thyroid disease requiring hormones or medication or TSH \< 0.5 or \> 5 mIU/L
  • Renal disease requiring dialysis
  • Known HIV infection
  • Active cancer or current chemotherapy treatment, or history of cancer requiring treatment in the past 5 years except for non-melanoma skin cancers or cancers that have clearly been cured
  • Current or past history of anorexia nervosa or bulimia nervosa
  • Current or past diagnosis of binge eating disorder
  • Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder)
  • Antiretroviral therapy (ART), including treatment for HIV, pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) within the past 3 months
  • Current celiac or diagnosed gluten intolerance or inflammatory bowel disease requiring specialized diet
  • Known severe allergy (e.g. anaphylaxis) to nuts or other foods
  • Systolic blood pressure (BP) \>160 mmHg and/or diastolic BP \>100 mmHg on at least 2 measurements during the clinical screening visit or resting heart rate \< 45 beats per minute or \>100 on 2 measurements during the clinical screening visit.
  • Known allergy to lidocaine or acetaminophen

Lab values

  • Diabetes (type 1 or 2 - HbA1c ≥ 6.5%, fasting glucose ≥ 126 mg/dL) or currently taking a glucose lowering medication
  • ALT or AST greater than 5 times the upper limit of normal or active gall bladder disease
  • Significant anemia (Hgb \< 10 g/dL) or thrombocytopenia (platelet count \< 60,000 /mm3)
  • Leukopenia defined as:
    • Males: WBC \< 3,100 /mm3 or (WBC 3,100 - \< 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result) Females: WBC \< 3,400 /mm3 or (WBC 3,400 - \< 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result)
  • Blood clotting disorder or INR \> ULN or PT \> ULN or (a)PTT \> ULN

Age

  • If 25-29 years old, \> 5% deviation from maximum weight (excluding weights while pregnant) since age 25 years
  • If at least 30 years old, \> 5% deviation from maximum weight (excluding weights while pregnant) in last 5 years or ≥ 10% deviation from maximum weight (excluding weights while pregnant) since age 30 years

Other

  • Any regular tobacco or nicotine use in the past year
  • Currently engaging in intense physical training or training for a sports event including, but not limited to, a marathon or body building
  • Currently pregnant, or less than one-year post-partum or actively planning to become pregnant within the next two years
  • Unwillingness to abstain from marijuana/cannabis use for 3 weeks at each of the four assessment time points
  • Currently enrolled in a supervised weight reduction program
  • Severely restricted diets: Vegan (no meat, fish, dairy, eggs, or honey), very low carbohydrate (\<15% calorie as carbohydrate), very low fat (\<15% calories as fat), or strictly gluten free
  • Night or rotating shift worker
  • Systolic blood pressure (BP) \<90 mmHg and/or diastolic BP \<60 mmHg on 2 measurements during the clinical screening visit.
  • Exceeds limitations to fit dual-energy X-ray absorptiometry (DXA) field of view
  • Non-compliance with appointments or tasks (food diaries, etc.) during the screening phase
  • Tendency to form thick or raised scars
  • At high risk for suicide, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)

Who the study is looking for

  • Age: 25 - \<60 years
  • BMI: 30 - \<40 kg/m2 at the first screening visit
  • Within 5% of current weight, for the past 6 months at the first screening visit
  • Able to participate in ergometry testing
  • Has a smart phone, tablet or computer with access to the internet

Age in the registry: 25 years to 59 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Columbia University Irving Medical Center
Coordinator of this site? Confirm its status
New YorkUnited StatesRecruiting
University of Pennsylvania
Coordinator of this site? Confirm its status
PhiladelphiaUnited StatesRecruiting
Drexel University
Coordinator of this site? Confirm its status
PhiladelphiaUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.